Examkin

Question

Difficulty: Very hardPreventive Care and Immunizations

A 32-year-old woman brings her 8-week-old daughter to the outpatient clinic for a scheduled preventive care encounter. The mother has a history of severe ulcerative colitis, which was managed with continuous intravenous infliximab therapy throughout her pregnancy; her most recent infusion occurred at 38 weeks gestation. The infant has been exclusively breastfed and demonstrates appropriate weight gain. Developmental assessment reveals that the infant coos, exhibits a social smile, and successfully tracks objects past the midline. Vital signs are within normal limits. Skin examination reveals a scattered eruption of small, firm, yellow-white papules surrounded by an erythematous halo over the trunk. The remainder of the physical examination is unremarkable. Which of the following is the most appropriate next step in the management of this patient?

  1. A
    Administer the first doses of DTaP, Hib, IPV, PCV, and rotavirus vaccines, and provide routine anticipatory guidance
  2. B
    Administer the first doses of DTaP, Hib, IPV, and PCV vaccines, and arrange for early intervention services due to language and motor deficits
  3. Administer the first doses of DTaP, Hib, IPV, and PCV vaccines, and omit the rotavirus vaccineAnswer
  4. D
    Postpone all scheduled immunizations until 6 months of age to allow complete clearance of transplacental monoclonal antibodies
  5. E
    Delay immunizations and prescribe a topical antimicrobial agent for the infant's truncal eruption

Answer

Administer the first doses of DTaP, Hib, IPV, and PCV vaccines, and omit the rotavirus vaccine
The correct management is to administer the scheduled inactivated vaccines (DTaP, Hib, IPV, and PCV) but omit the live-attenuated rotavirus vaccine. Infliximab is a monoclonal IgG1 antibody that actively crosses the placenta, especially during the third trimester. Infants born to mothers receiving this therapy are considered immunocompromised for the first 6 months of life due to persistent circulating levels of the biologic drug. Consequently, live-attenuated vaccines (e.g., rotavirus, BCG) are contraindicated during this window due to the risk of uncontrolled vaccine-strain infection. Inactivated vaccines are safe and must not be delayed. The infant's rash is erythema toxicum neonatorum, a benign condition, and her milestones are entirely normal for her age.

Step-by-Step Solution

1
Assess the impact of maternal infliximab therapy on the infant's immune status.
Infliximab is an IgG1 monoclonal antibody that crosses the placenta, particularly during the third trimester, leaving the infant transiently immunocompromised for up to 6 months of age.
Understanding placental transfer of biologics is required to determine vaccine safety.
2
Determine the appropriate vaccine schedule for a 2-month-old infant with transient immunosuppression.
Inactivated vaccines (DTaP, Hib, IPV, PCV) are safe and should be given on schedule. The live-attenuated rotavirus vaccine is contraindicated and must be omitted.
Live-attenuated vaccines carry a risk of disseminated, potentially fatal infection in immunocompromised hosts.
3
Evaluate the infant's dermatologic findings and developmental milestones.
The yellow-white papules on an erythematous base indicate erythema toxicum neonatorum, which is benign. The milestones (cooing, social smile, tracking past midline) are normal for 8 weeks.
Rules out the need to delay vaccines for acute illness or refer for developmental delay.

Key Concept

Immunization management in infants exposed to transplacental biologic immunosuppressants
Rate this question

Topics

Preventive Care and Immunizations

More questions from this topic